US 12403141
Deuterated MK2 pathway inhibitors and methods of using the same
granted A61KA61K31/506A61K45/06
Quick answer
US patent 12403141 (Deuterated MK2 pathway inhibitors and methods of using the same) held by Aclaris Therapeutics, Inc. expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aclaris Therapeutics, Inc.
- Grant date
- Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/506, A61K45/06, A61P, A61P35/00